Varicella zoster virus vaccine - Sinovac (Dalian) Vaccine Technology
Alternative Names: Live attenuated varicella vaccine - Sinovac Biotech/Dalian Vaccine Technology; PROVARIX; Varicella vaccine, live - Sinovac (Dalian) Vaccine Technology; Varicella zoster vaccine - Sinovac Biotech/Dalian Vaccine TechnologyLatest Information Update: 23 Aug 2024
At a glance
- Originator GlaxoSmithKline; Sinovac (Dalian) Vaccine Technology; Sinovac Biotech
- Developer Sinovac Biotech
- Class Attenuated vaccines; Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Varicella zoster virus infections
Most Recent Events
- 18 Jun 2024 Registered for Varicella zoster virus infections (In adolescents, In the elderly, Prevention, In adults) in China (IM)
- 01 Mar 2024 Phase-III clinical trials in Varicella zoster virus infections (Prevention, In infants) in Philippines (SC, Injection) (NCT06314724)
- 15 Aug 2023 Registered for Varicella zoster virus infections (Prevention) in Kenya, Lebanon (IM), prior to August 2023